Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-27
2008-08-19
Maier, Leigh C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S317000, C514S626000
Reexamination Certificate
active
07414039
ABSTRACT:
The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients.
REFERENCES:
patent: 4460360 (1984-07-01), Finegold
patent: 4879282 (1989-11-01), Saliba, Jr.
patent: 5037810 (1991-08-01), Saliba, Jr.
patent: 5104856 (1992-04-01), Esko et al.
patent: 5137528 (1992-08-01), Crose
patent: 5196405 (1993-03-01), Packman
patent: 5374624 (1994-12-01), Segel
patent: 5510386 (1996-04-01), Empfield et al.
patent: 5749845 (1998-05-01), Hildebrand et al.
patent: 6083933 (2000-07-01), Hahn
patent: 6110908 (2000-08-01), Guthery
patent: 6117877 (2000-09-01), Fogel
patent: 6255502 (2001-07-01), Penkler et al.
patent: 6648863 (2003-11-01), Reever
patent: 6740333 (2004-05-01), Beckett et al.
patent: 2004/0142968 (2004-07-01), Price et al.
patent: 2004/0161476 (2004-08-01), Hahn et al.
patent: 2004/0209960 (2004-10-01), Burgard et al.
patent: 2004/0248979 (2004-12-01), Brettman et al.
patent: WO 02/41837 (2002-05-01), None
Henry, R. et al “Absorption of alkalized intravesical lidocaine . . . ” J. Urology (2001) vol. 165, pp. 1900-1903.
Fukuda, T. et al “The effect of pH adjustment of 1% lidocaine . . . ” J. Anesth. (1994) vol. 8, pp. 293-296.
Buckley, M. et al “Characterization and immunohistochemical localization . . . ” Arch. Biochem. Biophys. (1996) vol. 330, No. 1, pp. 163-173.
Asklin, B. and J. Cassuto, “Intravesical Lidocaine in Several Interstitial Cystitis,”Scandinavian Journal of Urology and Nephrology, 1989, 23:311-2. (Exhibit 50).
Higson, R. H. et al., “Intravesical Lignocaine and Detrusor Instability,”British Journal of Urology, 1979, 51:500-3. (Exhibit 52).
Marrero, Ramon Perez et al., “Prolongation of Response to DMSO by Heparin Maintence,”Supplement to Urology, 1993, 41:64-6. (Exhibit 53).
Parsons, C. Lowell, “Evidence-based strategies for recognizing and managing IC,”Contemporary Urology, 2003, 1:270-7. (Exhibit 54).
Rovner, Eric et al., “Treatments Used in Women With Interstitial Cystitis: The Interstitial Cystitis Data Base (ICDB) Study Experience,”Urology, 2000, 1:285-90. (Exhibit 55).
Sethia, K. K. and J. C. Smith, “The Effect of ph and Lignocaine on Detrusor Instability,”British Journal of Urology, 1987, 60:516-8. (Exhibit 56).
Bernie, Jonathan E., et al, “The Intravesical Potassium Sensitivity Test and Urodynamics: Implications in a Large Cohort of Patients with Lower Urinary Tract Symptoms,”The Journal of Urology, Jul. 2001, 166:158-61. (Exhibit 1).
Bjerklund Johansen, Truls E. and Wolfgang Weidner, “Understanding Chronic Pelvic Pain Syndrome,”Current Opinion in Urology, 2002, 12:63-7. (Exhibit 2).
Forrest, John B. and Quang Vo, “Observations on the Presentation, Diagnosis and Treatment of Interstitial Cystitis in Men,”Urology, 2001, 57(Suppl 6A):26-9. (Exhibit 3).
Hakenberg, Oliver W. and Manfred P. Wirth, “Chronic Pelvic Pain in Men,”Urol Int, 2002, 68:138-43. (Exhibit 4).
Ho, Ngoc J., et al., “Natural History of Interstitial Cystitis in 274 Patients Receiving Sulfated Polysaccharide Therapy,”Urology, 1999, 53:1133-9. (Exhibit 5).
Indudhara, R. et al., “Interstitial Cystitis in Males,”Urology, Jun. 2001, 57 (Suppl 6A):120-1. (Exhibit 6).
Kusek, John W. and Leroy M. Nyberg, “The Epidemology of Interstitial Cystitis: Is it Time to Expand Our Definition?”Urology, 2001, 57(Suppl 6A):95-9. (Exhibit 7).
Lilly, Joel D. and C. Lowell Parsons, “Bladder Surface Glycosaminoglycans is a Human Epithelial Permeability Barrier,”Surgery, Dec. 1990, 171:493-6. (Exhibit 8).
Moldwin, Robert M., “Similarities Between Interstitial Cystitis and Male Chronic Pelvic Pain Syndrome,”Current Urology Reports, 2002, 3:313-8. (Exhibit 9).
Nickel, J. Curtis, et al., “Pentosan Polysulfate Therapy for Chronic Nonbacterial Prostatis (Chronic Pelvic Pain Syndrome Category IIIA): A Prospective Multicenter Clinical Trial,”Urology, 2000, 56:413-7. (Exhibit 10).
Novicki, Donald E., et al., “Interstitial Cystitis in Men,”Urology, 1998, 52:621-4. (Exhibit 11).
Parsons, C. L. et al., “Treatment of Interstitial Cystitis with Intravesical Heparin,”British Journal of Urology, 1994, 73:504-7. (Exhibit 12).
Parsons, C. Lowell, “Epithelial Coating Techniques in the Treatment of Interstitial Cystitis,”Urology, 1997, 49(Suppl 5A):100-4. (Exhibit 13).
Parson, C. Lowell, “Intravesical Potassium Sensitivity in Patients with Interstitial Cystitis and Urethral Syndrome,”Urology, 2001, 57:428-33. (Exhibit 14).
Parsons, C. Lowell, “Prostatitis, Interstitial Cystitis, Chronic Pelvic Pain, And Urethral Syndrome Share a Common Pathophysiology: Lower Urinary Dysfunctional Epithelium and Potassium Recycling,”Urology, 2003, 62:976-82. (Exhibit 15).
Parsons, C. Lowell, “Successful Downregulation of Bladder Sensory Nerves with Combination of Heparin and Alkalinized Lidocaine in Patients with Interstitial Cystitis,”Urology, 2005, 65:45-8. (Exhibit 16).
Parsons, C. Lowell, “The Therapeutic Role of Sulfated Polysaccharides in the Urinary Bladder,”Urologic Clinics of North America, Feb. 1994, 21(1):93-100. (Exhibit 17).
Parsons, C. Lowell and Michael Albo, “Intravesical Postassium Sensitivity in Patients with Prostatitis,”The Journal of Urology, Sep. 2002, 168:1054-57. (Exhibit 18).
Parsons, C. Lowell and Vasiliki Tatsis, “Prevalence of Insterstitial Cystitis in Young Women,”Urology, 2004, 64:866-70. (Exhibit 19).
Parsons, C. Lowell, et al., “Abnormal Urinary Potassium Metabolism in Patients with Interstitial Cystitis,”The Journal of Urology, Apr. 2005, 173: 1182-5. (Exhibit 20).
Parsons, C. Lowell, et al., “A Quantitatively Controlled Method to Study Prospectively Insterstitial Cystitis and Demonstrate the Efficacy of Pentosanpolysulfate,”The Journal of Urology, Sep. 1993, 150:845-8. (Exhibit 21).
Parsons, C. Lowell, et al., “Bladder-Surface Glycosaminoglycans: An Efficient Mechanism of Environmental Adaptation,”Science, May 9, 1980, 209(4444):605-7. (Exhibit 22).
Parsons, C. Lowell, et al., “Bladder-Surface Glycosaminoglycans: An Epithelial Permeability Barrier,”The Journal of Urology, Jan. 1990, 143:139-142. (Exhibit 23).
Parsons, C. Lowell, et al., “Effect of Pentosan Polysulfated Therapy On Intravesical Potassium Sensitivity,”Urology, 2002, 59:329-33. (Exhibit 24).
Parsons, C. Lowell, et al., “Epithelial Dysfunction in Nonbacterial Cystitis (Insterstitial Cystitis),”The Journal of Urology, Apr. 1991, 145:732-5. (Exhibit 25).
Parsons, C. Lowell, et al., “Increased Prevalence of Interstitial Cystitis: Previously Unrecognized Urologic and Gynecologic Cases Identified Using A New Symptom Questionnaire and Intravesical Potassium Sensitivity,”Urology, 2002, 60:573-8. (Exhibit 26).
Parsons, C. Lowell, et al., “Quantifying Symptoms in Men with Interstitial Cystitis/Prostatis, and its Correlation with Potassium-Sensitivity Testing,”BJU International, 2005, 95:86-90. (Exhibit 27).
Parsons, C. Lowell, et al, “The Prevalence of Interstitial Cystitis in Gynecologic Patients with Pelvic Pain, As Detected by Intravesical Potassium Sensitivity,”American Journal of Obstetrics and Gynecology, Nov. 2002, 187(5):1-10. (Exhibit 28).
Parsons, C. Lowell, et al., “The Role of Urinary Potassium in the Pathogenesis and Diagnosis of Interstitial Cystitis,”The Journal of Urology, Jun. 1998, 159(6):1862-7. (Exhibit 29).
Saada, Janak, et al., “Computed Tomography and Magnetic Resonance Imaging in the Management of Prostate Cancer,” Textbook of Prostatitis, pp. 169-176. (Exhibit 30), 19
Foley & Lardner LLP
Maier Leigh C
Reiter Stephen E.
The Regents of the University of California
LandOfFree
Interstitial therapy for immediate symptom relief and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interstitial therapy for immediate symptom relief and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interstitial therapy for immediate symptom relief and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4007198